Skip to main content
. 2022 Apr 5;77:103584. doi: 10.1016/j.amsu.2022.103584

Table 1.

Systematic review.

Investigatiors
Table 1: Systematic Review
Title of study Year Patients (n) Preoperative BMI (kg/m^2) Reflux evaluation Follow-up (mo) GERD (%)
Bougie size (F)
Preoperative Postoperative
M.E. Abd Ellatif et al. [16] Long term predictors of success after laparoscopic sleeve gastrectomy 2014 1395 46 Upper GI endoscopy 84 11.4 <36 (837) - >44 (558)
Albanopoulos et al. [17] The impact of laparoscopic sleeve gastrectomy on weight loss and obesity-associated comorbidities: the results of 3 years of follow up 2016 88 47.8 Symptoms 36 27 9.2 34
Alexandrou et al. [18] Laparoscopic sleeve gastrectomy for morbid obesity: 5 year results 2015 30 55.5 ± 1.7 Esofagogastroscopy 60 16 29
Althuwaini et al. [19] Prevalence and predictors of gastroesophageal reflux disease after laparoscopic sleeve gastrectomy 2018 213 47,84 GERD-Health-Related-Quality of Life questionnaire 12 47% 32
Angrisani et al. [20] Five year results of laparoscopic sleeve gastrectomy: effects on gastroesophageal reflux disease symptoms and co-morbidities 2016 105 group1: <50; group2:>50 symptoms, gastrointestinal endoscopy, double contrast barium swallow 60 group 1: 31% group 2: 25% group 1: 18,2% group: 20% 40
Arman et al. [21] Long-term (11+years) outcomes in weight patient satisfaction, comorbidities, and gastroesophageal reflux treatment after laparoscopic sleeve gastrectomy 2016 110 38,8 medication use 132 11.1 21.4 34
Barr et al. [22] GERD and acid reduction medication use following gastric bypass and sleeve gastrectomy 2017 147 49.1 ± 8 acid reduction medication (ARM) utilization, Gastroesophageal reflux disease health-related quality of life (GERD-HRQL) 12 N.R. N.R. 36–40
Barry et al. [23] Laparoscopic vertical sleeve gastrectomy: a 5 year veterans affairs review 2017 223 45.4 (from 33 to 56.6) medication use 60 56 13 34
Berry et al. [24] Sleeve gastrectomy outcomes in patients with BMI between 30 and 35-3 years of follow-up 2018 252 32.3 (30–35) gastrointestinal endoscopy, barium esophagogram, esophageal manometry, esophageal pH test 36 25,43 64,6 improvement of their symptoms - 2.4 de novo symptoms 36
Borbely et al. [25] De novo gastroesophageal reflux disease after sleeve gastrectomy: role of preoperative silent reflux 2018 222 49.6 ± 7.2 questionnaires, upper endoscopy, 24 h-pH manometry, esophagogram, medication use 32 25 silent GERD preop - 23 with preoperative diagnosis of GERD 52 32
Boza et al. [26] Long-term outcomes of laparoscopic sleeve gastrectomy as a primary bariatric procedure 2014 161 34.9 (33.3–37.5) GERD symptoms questionnaires, endoscopy 60 4.3 26.7 60
Braghetto et al. [27] Prevalence of Barrett's esophagus in bariatric patients undergoing sleeve gastrectomy 2016 231 38.4 + 3.1 clinical evaluation, Endoscopy 60 0 (patients with GERD didn't undergo sleeve gastrectomy) 23.2 34
Braghetto et al. [28] Late esophagogastric anatomic and functional changes after sleeve gastrectomy and its clinical consequences with regards to gastroesophageal reflux disease 2019 248 38.4 ± 3,4 reflux symptoms and Upper gastrointestinal ednoscopy 60 0 65,1 N.R.
Burgerhart et al. [29] Effect of sleeve gastrectomy on gastroesophageal reflux 2014 20 47.6 ± 6.1 esophageal function tests (high resolution manometry and 24-h pH impedence metry); reflux disease questionnaire 3 70 20 34
Carabotti et al. [30] Impact of laparoscopic sleeve gastrectomy on upper gastrointestinal symptoms 2013 97 respondent patients: 45.9; non respondent patients: 43.3 questionnaire for upper GI symptoms following Roma III criteria 13 27 25,67 42
Carter et al. [31] Association between gastroesophageal reflux disease and laparoscopic sleeve gastrectomy 2011 206 46.6 symptoms, medication use, upper gastrointestinal radiography 24 34.6 49 complained of immediate GERD symptoms; 47.2had persistent GERD symptoms that lasted >1 month after LSG; 33.8% were taking medication specifically for GERD after LSG 34
Castagneto Gissey et al. [32] 10-year follow-up after laparoscopic sleeve gastrectomy: outcomes in a monocentric series 2018 182 46.6 ± 7.3 clinical symptomatology referred by patients on a symptom assessment scale, esophagogastroduodenoscopy if necessary 120 18.9 42.9 48
Catheline et al. [33] Five year results of sleeve gastrectomy 2013 65 49.9 ± 9.1 range (35.7–71.8) PPI medication, symptoms, endoscopy 60 11.1 33.3 34
Chuffart et al. [34] Long-term results after sleeve gastrectomy for gastroesophageal reflux disease: a single-center French study 2017 64 47 ± 8 upper GI endoscopy, symptoms, medication (PPI) 72 26.8 42 36
Coupaye et al. [35] Gastroesophageal reflux after sleeve gastrectomy: a prospective mechanistic study 2018 119 43.3 ± 5.7 HRM(high-resolution esophageal manometry), APM(ambulatory 24-h esophageal pH monitoring), upper endoscopy 12 34 52 (patients without preoperative GERD); 56,25 (patients with preoperative GERD) 36
Dakour Aridi et al. [36] Gastroesophageal reflux disease after laparoscopic sleeve gastrectomy with concomitant hiatal hernia repair: an unresolved question 2017 165 44.1 ± 10.7 (LSG), 42.7 ± 15.3 (LSG + HHR) symptoms, PPI use 24 41.6 (LSG)61.8 (LSG + HHR) 46.2 (LSG) - 41.4 (LSG + HHR) 36/40
Del Genio et al. [37] Sleeve Gastrectomy and development of “de novo” gastroesophageal reflux 2014 25 46.1 (38–58) multichannel intraluminal impedance and pH (MII-pH), High-resolution manometry with impedance (HRiM), questionnaire 13 (11–17) N.R. N.R. 40
DuPree et al. [38] Laparoscopic sleeve gastrectomy in patients with preexisting Gastroesophageal Reflux disease. A National Analysis 2014 4832 47.9 REflux symptoms and Upper gastrointestinal ednoscopy 6 44.5 84.1 continued to have GERD symptoms N.R.
Felsenreich et al. [39] Update: 10 years of sleeve gastrectomy- the first 103 patients 2018 103 49 ± 9.1 gastroscopies, manometries, 24-h pH metries, reflux symptom index questionnaire 120 N.R. 57 N.R.
DM Felsenreich et al. [40] Reflux, Sleeve Dilation, and Barret's Esophagous after Laparoscopic Sleeve Gastrectomy: Long-Term Follow-Up 2017 43 49.5 ± 9,6 REflux symptoms and Upper gastrointestinal ednoscopy 129 0 38 42–48
Flolo et al. [41] Five-year outcomes after vertical sleeve gastrectomy for severe obesity: a prospective cohort study 2017 168 46.2 ± 6.4 symptoms, medication use 60 12 35 32
Gadiot et al. [42] Long-term results of laparoscopic sleeve gastrectomy for morbid obesity: 5 to 8-year results 2017 277 44.8 ± 6.7 symptoms 60 10.1 7 (9pz) N.R.
Garg et al. [43] Mid to long term outcomes of laparoscopic sleeve gastrectomy in Indian population: 3–7 years results - a retrospective cohort study 2017 424 46.67 ± 15.8 upper gastrointestinal endoscopy, GERD severity symptom questionnaire, PPI intake 60 16.5 2.8 36
Gemici et al. [44] Outcomes of laparoscopic sleeve gastrectomy by means of esophageal manometry and pH-metry, before and after surgery 2020 62 47.91 ± 6.23 Upper gastrointestinal endoscopy, 24 h pH-monitoring (APM), Esophageal manometry (EM) 36 N.R. N.R. 36
Genco et al. [45] Gastroesophageal reflux disease and Barrett's esophagus after laparoscopic sleeve gastrectomy: a possible, underestimated long-term complication 2017 162 45.8 ± 6.3 visual analogue scale (VAS) evaluation of GERD symptoms, PPIs consumption recording, esophagogastroduodenoscopy (EGD) 58 33.6 68.1 48
Georgia et al. [46] 24-h multichannel intraluminal impedance PH-metry 1 year after laparoscopic sleeve gastrectomy: an objective assessment of gastroesophageal reflux disease 2017 12 48.97 24-h multichannel intraluminal impedance-pH metry (MIIpH) pre-and 12 months post-LSG; symptoms; EGD 12 42.06.00 83.33 38
Hendricks et al. [47] Impact of sleeve gastrectomy on gastroesophageal reflux disease in a morbidly obese population undergoing bariatric surgery 2016 919 N.R. symptoms, PPI treatment, upper gastrointestinal endoscopy (UGI), esophagogastroduodenoscopy (EGD), pH manometry 24 group B 1% (13) group A 3% (25) 38
Himpens et al. [48] Long-term results of laparoscopic sleeve gastrectomy for obesity 2010 53 39 (range, 31–57; SD, 5.4) Bariatric analysis and reporting outcome system (BAROS) score 72 3.3 23 34
Hirth et al. [49] Laparoscopic sleeve gastrectomy: long-term weight loss outcomes 2015 16 43.5 medications, symptoms 84 35 35 32
Howard et al. [50] Gastroesophageal reflux after sleeve gastrectomy in morbidly obese patients 2011 28 55.5 range (39–80) upper gastrointestinal radiographic swallow study, GERD score questionnaire, symptoms, medication use 32 25 39 38
Kehagias et al. [51] Efficacy of sleeve gastrectomy as sole procedure in patients with clinically severe obesity (BMI <50 kg/m^2) 2013 203 43.2 ± 2.8 PPi prescription 36 0 7,4 32
Kowalewski et al. [52] Long-term outcomes of laparoscopic sleeve gastrectomy-a single-center, retrospective study 2018 84 51.6 typical symptoms, PPi therapy 96 N.R. 60 36
Lemaitre et al. [53] Laparoscopic sleeve gastrectomy in the South Pacific. Retrospective evaluation of 510 patients in a single institution 2016 384 47.8 ± 7.8 PPi therapy, endoscopic diagnosis, symptoms 24 N.R. 9.4 33
Lim et al. [54] Correlation between symptomatic gastro-esophageal reflux disease (GERD) and erosive esophagitis (EE) post vertical sleeve gastrectomy (VSG) 2019 63 42.1 ± 1.2 questionnaire that included documentation of reflux symptomatology, medication use; EGD 13 31.7 47.6 36
Menenakos et al. [55] Laparoscopic sleeve gastrectomy performed with intent to treat morbid obesity: a prospective single-center study of 261 patients with a median follow-up of 1 year 2010 261 45.2 (range 32.1–72.7) upper gastrointestinal endoscopy 12 N.R. 25 38
Nocca et al. [56] Five-year results of laparoscopic sleeve gastrectomy for the treatment of severe obesity 2017 1050 44.58 ± 7.71 symptoms 60 21.27 39.1 36
Pilone et al. [57] Gastroesophageal reflux after sleeve gastrectomy: new onset and effect on symptoms on a prospective evaluation 2019 104 44.2 ± 4.2 GERD-HRQL questionnaire, EGDS, PPI use 12 27.9 10.6 32
Pok et al. [58] Laparoscopic sleeve gastrectomy in Asia: long term outcome and revisional surgery 2016 61 37.3 ± 8.1 (range20.8–75.3) symptoms 60 N.R. 17 36
Rawlins et al. [59] Sleeve gastrectomy 5 year outcomes of a single institution 2013 49 65 (range 39–106) patient report 60 N.R. 11 26.4
Rebecchi et al. [60] Gastroesophageal reflux disease and laparoscopic sleeve gastrectomy: a physiopathologic evaluation 2014 71 44.3 ± 3.8 gastroesophageal reflux disease symptom assessment scale (GSAS), esophageal manometry and 24-h pH monitoring, DeMeester composite reflux score 48 group A: 42.3 group B: 0 group A: symptoms improved group B: 5.4 36
Sharma et al. [61] Evaluation of gastroesophageal reflux before and after sleeve gastrectomy using symptom scoring, scintigraphy, and endoscopy 2014 32 47.8 Carlsson Dent Questionnaire and GERD questionnaire to assess Symptom-Severity score, upper GI endoscopy, radionuclide scintigraphy 12 6.25 (2pz) 78.1 36
Sheppard et al. [62] Rates of reflux before and after laparoscopic sleeve gastrectomy for severe obesity 2015 205 48.5 ± 9.7 symptoms, medication use 12 25.5 58 increased PPI - 42 continued the same treatment - 0 decreased 50
Soricelli et al. [63] Lack of correlation between gastroesophageal reflux disease symptoms and esophageal lesions after sleeve gastrectomy 2018 219 46.2 ± 7.2 EGD, VAS evaluation of GERD symptoms, PPI consumption 66 40.9 70.2 48
Viscido et al. [64] Laparoscopic sleeve gastrectomy: endoscopic findings and gastroesophageal reflux symptoms at 18-month follow-up 2018 109 47.8 ± 16 questionnaire, GERD symptoms, EGD 18 33 44 42